Biogen (BIIB) Competitors $155.52 -0.48 (-0.31%) (As of 10:25 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BIIB vs. TEVA, PNW, POR, REGN, ALNY, UTHR, INCY, NBIX, BMRN, and EXASShould you be buying Biogen stock or one of its competitors? The main competitors of Biogen include Teva Pharmaceutical Industries (TEVA), Pinnacle West Capital (PNW), Portland General Electric (POR), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), and Exact Sciences (EXAS). Biogen vs. Teva Pharmaceutical Industries Pinnacle West Capital Portland General Electric Regeneron Pharmaceuticals Alnylam Pharmaceuticals United Therapeutics Incyte Neurocrine Biosciences BioMarin Pharmaceutical Exact Sciences Teva Pharmaceutical Industries (NYSE:TEVA) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, community ranking, earnings, profitability, valuation, dividends and institutional ownership. Is TEVA or BIIB more profitable? Biogen has a net margin of 16.81% compared to Teva Pharmaceutical Industries' net margin of -5.73%. Teva Pharmaceutical Industries' return on equity of 42.92% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-5.73% 42.92% 7.25% Biogen 16.81%14.98%8.59% Does the MarketBeat Community prefer TEVA or BIIB? Biogen received 479 more outperform votes than Teva Pharmaceutical Industries when rated by MarketBeat users. Likewise, 71.84% of users gave Biogen an outperform vote while only 67.77% of users gave Teva Pharmaceutical Industries an outperform vote. CompanyUnderperformOutperformTeva Pharmaceutical IndustriesOutperform Votes132567.77% Underperform Votes63032.23% BiogenOutperform Votes180471.84% Underperform Votes70728.16% Which has more risk & volatility, TEVA or BIIB? Teva Pharmaceutical Industries has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Biogen has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Do analysts recommend TEVA or BIIB? Teva Pharmaceutical Industries currently has a consensus target price of $19.67, suggesting a potential upside of 15.52%. Biogen has a consensus target price of $258.96, suggesting a potential upside of 66.00%. Given Biogen's higher possible upside, analysts plainly believe Biogen is more favorable than Teva Pharmaceutical Industries.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Biogen 0 Sell rating(s) 13 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.54 Which has better valuation and earnings, TEVA or BIIB? Biogen has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$15.85B1.22-$559M-$0.85-20.03Biogen$9.84B2.31$1.16B$11.0714.09 Do insiders and institutionals hold more shares of TEVA or BIIB? 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 0.2% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer TEVA or BIIB? In the previous week, Biogen had 48 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 56 mentions for Biogen and 8 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.98 beat Biogen's score of 0.66 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 22 Very Positive mention(s) 4 Positive mention(s) 21 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Positive SummaryBiogen beats Teva Pharmaceutical Industries on 12 of the 18 factors compared between the two stocks. Ad Angel PublishingTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIIB vs. The Competition Export to ExcelMetricBiogenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.73B$2.93B$5.05B$8.82BDividend YieldN/A1.89%5.17%4.07%P/E Ratio14.0945.44125.6917.78Price / Sales2.31359.341,179.7874.25Price / Cash8.68160.0933.7732.53Price / Book1.533.734.684.68Net Income$1.16B-$41.63M$119.54M$226.08M7 Day Performance-5.91%-7.95%-2.46%-2.04%1 Month Performance-17.96%-7.17%-4.08%0.06%1 Year Performance-32.21%23.03%29.82%24.60% Biogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIIBBiogen4.8648 of 5 stars$155.52-0.3%$257.20+65.4%-32.2%$22.66B$9.84B14.057,570Analyst DowngradeTEVATeva Pharmaceutical Industries2.7027 of 5 stars$17.06+0.2%$19.67+15.3%+80.0%$19.33B$15.85B-20.0337,851PNWPinnacle West Capital3.6534 of 5 stars$92.12+0.4%$82.04-10.9%+28.0%$10.47B$4.70B17.386,133Analyst DowngradePORPortland General Electric3.7758 of 5 stars$47.01+0.3%$48.86+3.9%+14.8%$4.96B$2.92B13.992,842Positive NewsREGNRegeneron Pharmaceuticals4.7877 of 5 stars$738.30-0.7%$1,099.55+48.9%-7.3%$81.13B$13.12B18.4013,450Positive NewsALNYAlnylam Pharmaceuticals4.3981 of 5 stars$248.40-0.2%$298.09+20.0%+50.5%$32.04B$1.83B0.002,100Analyst ForecastUTHRUnited Therapeutics4.5219 of 5 stars$363.78-0.2%$370.86+1.9%+59.1%$16.24B$2.33B16.001,168Analyst RevisionPositive NewsINCYIncyte3.912 of 5 stars$70.48-0.8%$77.16+9.5%+29.9%$13.58B$3.70B507.542,524Analyst ForecastNBIXNeurocrine Biosciences4.9552 of 5 stars$124.01+0.6%$163.91+32.2%+12.7%$12.56B$1.89B33.051,400Positive NewsBMRNBioMarin Pharmaceutical4.9884 of 5 stars$61.87-1.1%$94.20+52.3%-28.5%$11.79B$2.42B37.463,401Analyst RevisionEXASExact Sciences4.8873 of 5 stars$53.63+1.8%$74.47+38.9%-21.7%$9.93B$2.50B-44.696,600Positive News Related Companies and Tools Related Companies Teva Pharmaceutical Industries Competitors Pinnacle West Capital Competitors Portland General Electric Competitors Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors United Therapeutics Competitors Incyte Competitors Neurocrine Biosciences Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BIIB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIIB Stock Alerts